Brief: WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
25/03/2025 11:48
March 25 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK: WUXI BIOLOGICS FY ADJUSTED NET INCOME RMB 5,396.9 MILLION Source text: ID:nPn97tpBja Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln